The guiding principle is global information accessibility.
Learn more about this primarily cancer-driven research landscape.
Which firms are ripe for the picking this year?
From our Oct. 15 issue: One sample, one test, many results—this familiar approach is being applied ever more broadly, generating epigenetic, mutational, and signaling profiles.
Check out these websites from GEN's Best of the Web.
From our Oct. 15 issue: To cast cancer’s dysregulated pathways in a new light, researchers are trying new angles, illuminating epigenetic and post-transcriptional dimensions.
We see the future in a drop of blood.
Be sure to add email@example.com
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved